Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER

NCT01863693 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01863693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01863693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
May 10, 2013
Completion date
June 15, 2018
Enrollment
300 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer